Shikari® Ranibizumab ELISA Kit

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment specifically engineered for intraocular use. It functions as a VEGF-A antagonist by binding to and neutralizing the biologically active isoforms of VEGF-A, including VEGF110. This mechanism blocks the interaction between VEGF-A and its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, thereby inhibiting downstream processes such as endothelial proliferation, vascular leakage, and angiogenesis. These actions are crucial in mitigating pathologic neovascularization, particularly in the retinal environment.

Clinically, ranibizumab is primarily utilized in the treatment of age-related macular degeneration (AMD), where abnormal blood vessel formation and leakage contribute to progressive vision loss. By halting VEGF-A activity, ranibizumab slows the progression of the neovascular form of AMD, offering patients a chance at vision stabilization and, in some cases, improvement. Its targeted mechanism and localized ocular administration help limit systemic exposure, which is critical for reducing off-target effects in vulnerable patient populations.

In a research context, ranibizumab serves as an important tool for studying angiogenesis, endothelial signaling, and VEGF-mediated ocular disease mechanisms. It is also of interest in therapeutic drug monitoring (TDM) for evaluating patient-specific responses, ensuring optimal therapeutic levels, and identifying anti-drug antibody (ADA) formation that could impair efficacy. As a biologic, the immunogenicity of ranibizumab and the potential for ADA generation remain key considerations in both clinical and translational research settings.

This product is manufactured in Turkey by Matriks Biotek.